ライフサイエンスコーパス: late gadolinium enhancement

1 h normal ventricular function (4/5, 80% with late gadolinium enhancement).

2 y T1 mapping, rest first pass perfusion, and late gadolinium enhancement.

3 haracterisation with a suggestive pattern of late gadolinium enhancement.

4 Microvascular obstruction was assessed with late gadolinium enhancement.

5 o subjects in groups 3 and 4 had evidence of late gadolinium enhancement.

6 bal distribution is not well visualized with late gadolinium enhancement.

7 e features such as diastolic dysfunction and late gadolinium enhancement.

8 enhancement and edema exceeding the area of late gadolinium enhancement.

9 ion by LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement.

10 ipants, 114 had a visible myocardial scar by late gadolinium enhancement.

11 Multivariable analysis adjusted for late gadolinium enhancement.

12 ) and showed intramyocardial and pericardial late gadolinium enhancement.

13 sudden death risk factors and 50 (37%) with late gadolinium enhancement.

14 No subjects had late gadolinium enhancement.

15 sment of myocardial perfusion, function, and late gadolinium enhancement.

16 Viability was assessed using late gadolinium enhancement.

17 n (r=0.37-0.47) but not with the presence of late gadolinium enhancement.

18 T2-prepared steady-state-free precession, or late gadolinium enhancement.

19 rosis was identified by a diffuse pattern of late gadolinium enhancement.

20 t of dyskinetic area, and score of extent of late gadolinium enhancement.

21 ersisted after adjusting for the presence of late gadolinium enhancement.

22 baseline and 12 months, inclusive of T2 and late gadolinium enhancement.

23 s were reported in 2 females with low T1 and late gadolinium enhancement.

24 ness, T2, extracellular volume fraction, and late gadolinium enhancement.

25 cantly more specific than LVEF >35% with any late gadolinium enhancement.

26 indexed ECV (iECV) to body surface area and late gadolinium enhancement.

27 tor of 6-month wall thickening compared with late gadolinium enhancement.

28 77.8% (14/18) of patients had focal late gadolinium enhancement.

29 characterization of replacement fibrosis by late gadolinium enhancement.

30 d with those of other cardiac MR parameters (late gadolinium enhancement, 0.90; T2 ratio, 0.79; extra

31 proportion of total left ventricular mass (%late gadolinium enhancement; 10.4+/-13.2% versus 8.5+/-8

32 correlating with the presence or absence of late gadolinium enhancement (1001+/-82 versus 891+/-38 m

33 ACE (1.8%) than those with both ischemia and late gadolinium enhancement (12.0%; P<0.001).

34 y larger than the infarct size quantified by late gadolinium enhancement (37.2+/-11.6% versus 22.3+/-

35 atients without and in patients with evident late gadolinium enhancement (466 msec +/- 14, 406 msec +

36 ubset of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index

37 The presence of late gadolinium enhancement (65% versus 64%; P=0.99) and

38 lar ejection fraction (73% versus 68%), more late gadolinium enhancement (85% versus 15%), and a lowe

39 ith DSP and were strongly associated with LV late gadolinium enhancement (90%), even in cases of acut

40 rdial structural and functional adaptations (late gadolinium enhancement/abnormal innervation) with d

41 FDG uptake, as well as transmural extent of late gadolinium enhancement, acutely can identify viable

42 epolarization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

43 cipants with myocardial scar determined with late gadolinium enhancement and 286 age-, sex-, and ethn

44 rdiovascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

45 agnetic resonance showed regional transmural late gadolinium enhancement and edema exceeding the area

46 Both transmural extent of late gadolinium enhancement and FDG uptake on the acute

47 iagnosed with ALVC, defined as a LV isolated late gadolinium enhancement and fibro-fatty replacement

48 Across all FD, late gadolinium enhancement and low native T1 were indep

49 cular magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sar

50 ver, this zone was most commonly spared from late gadolinium enhancement and T2 abnormalities, typica

51 All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imagin

52 dex, T1, T2, global longitudinal strain, and late gadolinium enhancement) and biomarkers (high-sensit

53 ith late gadolinium enhancement (ventricular late gadolinium enhancement) and diffuse fibrosis with p

54 aging was performed to quantify regional (by late-gadolinium enhancement) and diffuse (by T1 mapping)

55 CMR DENSE, late gadolinium enhancement, and electrical timing toget

56 with presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricu

57 enosine stress/rest perfusion, cine imaging, late gadolinium enhancement, and magnetic resonance coro

58 nd adenosine stress perfusion, cine imaging, late gadolinium enhancement, and MR coronary angiography

59 eling and function, infarct size assessed by late gadolinium enhancement, and myocardial strain.

60 cine, strain imaging by myocardial tagging, late gadolinium enhancement, and native T1 mapping (Shor

61 was performed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping.

62 Spatial associations among stress perfusion, late gadolinium enhancement, and T2 imaging were made at

63 as performed, followed by CMR (cine imaging, late gadolinium enhancement, and T2-weighted imaging and

64 Cine, stress perfusion, late gadolinium enhancement, and T2-weighted imaging tec

65 ic myocardial velocities, scar determined by late gadolinium enhancement, and wall motion abnormaliti

66 dvanced disease controls increased T2 in the late gadolinium enhancement area (57+/-6 versus 60+/-7 m

67 ad higher troponin T peak (P<0.0001), larger late gadolinium enhancement area (P<0.0001), and lower l

68 higher troponin T peak (P=0.006) but similar late gadolinium enhancement area (P=0.24) compared with

69 05), and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared with 14% in HTN

70 parisons of HCM subjects without evidence of late gadolinium enhancement, as well as of hypertensive

71 ardiac magnetic resonance imaging, including late gadolinium enhancement assessment of fibrosis.

72 A total of 72 patients (72%) showed late gadolinium enhancement at baseline with 57 (57%) ha

73 ed native/postcontrast T1 maps, T2 maps, and late gadolinium enhancement at days 1 and 21 post-MI.

74 The presence of late gadolinium enhancement at magnetic resonance imagin

75 The presence of late gadolinium enhancement at magnetic resonance imagin

76 There was no change in volume of late gadolinium enhancement at treatment.

77 CMR, including T2-weighted edema imaging and late gadolinium enhancement before coronary angiography.

78 he prognostic value of inducible ischemia or late gadolinium enhancement by CMR.

79 findings of left ventricular hypertrophy and late gadolinium enhancement can be used to identify pati

80 The association of scar on late gadolinium enhancement cardiac magnetic resonance (

81 Scar signal quantification using late gadolinium enhancement cardiac magnetic resonance (

82 prognostic value of the peri-infarct zone on late gadolinium enhancement cardiac magnetic resonance i

83 diac electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance s

84 diomyopathy and drug-refractory VT underwent late gadolinium enhancement cardiac MRI (CMR), (123)I-me

85 nne muscular dystrophy, myocardial damage by late gadolinium enhancement cardiac MRI and preserved ej

86 Late-gadolinium-enhancement cardiac MRI (LGE-MRI) assess

87 d eighteen consecutive patients referred for late gadolinium enhancement-cardiac magnetic resonance a

88 Future studies should confirm whether late gadolinium enhancement-cardiac magnetic resonance a

89 Late gadolinium enhancement-cardiac magnetic resonance i

90 tected by midwall hyperenhancement (MWHE) on late gadolinium enhancement cardiovascular magnetic reso

91 ted the significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic reso

92 with HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic reso

93 extensive) myocardial scarring identified by late gadolinium enhancement cardiovascular magnetic reso

94 t recipients, myocardial fibrosis is seen on late gadolinium enhancement cardiovascular magnetic reso

95 to determine whether myocardial fibrosis on late gadolinium enhancement cardiovascular magnetic reso

96 Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic reso

97 DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic reso

98 Cine and late gadolinium enhancement cardiovascular MR and 2-dime

99 Late gadolinium enhancement-cardiovascular magnetic reso

100 Conversely, late gadolinium enhancement CMR should be postponed in t

101 Cine and late gadolinium enhancement CMR were performed in 333 co

102 adenosine stress 3D myocardial perfusion and late gadolinium enhancement CMR.

103 UMI was defined as the presence of late gadolinium enhancement consistent with MI in the ab

104 The edema volume in late gadolinium enhancement correlated well with edema v

105 Infarct size (late gadolinium enhancement) decreased after CSC infusio

106 Indexed MRI-late gadolinium enhancement-defined infarct size was 18.

107 In individuals without a late gadolinium enhancement-defined myocardial scar (n =

108 d on CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium enhancement detection showed a higher pe

109 .0+/-5.2% ( P=0.0001) with prevalence of any late gadolinium enhancement dropping to 48%.

110 ardial perfusion, microvascular obstruction, late gadolinium enhancement, edema, and intramyocardial

111 Patients without ischemia or late gadolinium enhancement experienced a lower annual e

112 demonstrated that (18)F-FDG extent exceeded late gadolinium enhancement extent (33.2+/-16.2% left ve

113 Global late gadolinium enhancement extent dropped from 8.5+/-9.

114 Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were asse

115 Late gadolinium enhancement for replacement fibrosis was

116 t ventricular (LV) volumes and function, and late gadolinium enhancement for the detection of myocard

117 CMR, 98% completed stress CMR, 82% completed late gadolinium enhancement for viability, 94% completed

118 for a permanent pacemaker and LVEF >35% with late gadolinium enhancement >5.7%, had high annualized e

119 tween higher baseline hs-cTnT categories and late gadolinium enhancement (>/=7.42 ng/L versus <limit

120 rd ratio=2.18 [1.3-3.8]) and the presence of late gadolinium enhancement (hazard ratio=2.2 [1.4-3.6])

121 Late gadolinium enhancement, however, relies on the regi

122 In parallel, late gadolinium enhancement identified the extent of myo

123 Microvascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes

124 Late gadolinium enhancement images were acquired to dete

125 Late gadolinium enhancement images were blindly interpre

126 ng stenosis was removed, and T2-weighted and late-gadolinium-enhancement images were acquired.

127 cardium were identified from postreperfusion late-gadolinium-enhancement images.

128 tients underwent CMR including cine imaging, late gadolinium enhancement imaging (LGE) (replacement f

129 Late gadolinium enhancement imaging is an established me

130 Late gadolinium enhancement imaging was abnormal in 79 p

131 Quantification of fibrosis from late gadolinium enhancement imaging was incrementally pe

132 dilator first pass myocardial perfusion, and late gadolinium enhancement imaging), transthoracic echo

133 sted of cine, rest first-pass perfusion, and late gadolinium enhancement imaging.

134 magnetic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients,

135 Preoperative CMR showed late gadolinium enhancement in 70% of the patients, wher

136 One subject in group 2 had late gadolinium enhancement in a noncoronary distributio

137 with normal LV contractility and absence of late gadolinium enhancement in all but one patient.

138 There was no late gadolinium enhancement in any of the participants b

139 al role for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and nonin

140 cant increase in the frequency of noninfarct late gadolinium enhancement in PA (70%) when compared wi

141 e of cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left vent

142 went CMR at 1.5 T including cine, DENSE, and late gadolinium enhancement in subjects >45 years.

143 , underwent CMR at 3.0 T including cine, and late gadolinium enhancement in subjects >45 years.

144 Cardiac magnetic resonance showed LV late gadolinium enhancement in the LV lateral and poster

145 ease in early disease stages and complements late gadolinium enhancement in visualization of the regi

146 cardial injury could improve the accuracy of late gadolinium-enhancement in predicting functional rec

147 reported for any mice, and the first use of late-gadolinium-enhancement in a mouse model of congenit

148 Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibro

149 magnetic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular f

150 expansion wave was inversely correlated with late-gadolinium enhancement infarct mass (r=-0.81; P<0.0

151 with a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection f

152 Cardiac magnetic resonance late gadolinium enhancement (LGE) and feature-tracking a

153 rdiac magnetic resonance imaging pericardial late gadolinium enhancement (LGE) and inflammatory bioma

154 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE

155 netic resonance (CMR) protocol incorporating late gadolinium enhancement (LGE) and magnetic resonance

156 gate the association between local CV versus late gadolinium enhancement (LGE) and myocardial wall th

157 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is eme

158 y parameters at diagnosis predict dynamic of late gadolinium enhancement (LGE) as persistent LGE has

159 nd function and tissue characterization with late gadolinium enhancement (LGE) as well as T1 and T2 m

160 y, there are scarce data on the influence of late gadolinium enhancement (LGE) assessed by cardiovasc

161 right ventricular quantitative analysis and late gadolinium enhancement (LGE) assessments and analyz

162 cidence of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic re

163 Late gadolinium enhancement (LGE) border zone on cardiac

164 cohort studies have evaluated the ability of late gadolinium enhancement (LGE) by cardiac magnetic re

165 Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic re

166 Late gadolinium enhancement (LGE) by cardiac MR (CMR) is

167 Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,

168 ave reported an inverse relationship between late gadolinium enhancement (LGE) cardiac magnetic reson

169 Late gadolinium enhancement (LGE) cardiac magnetic reson

170 We investigated whether late gadolinium enhancement (LGE) cardiovascular magneti

171 We hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magneti

172 te for VT, can be noninvasively defined with late gadolinium enhancement (LGE) cardiovascular magneti

173 Late gadolinium enhancement (LGE) cardiovascular magneti

174 Late gadolinium enhancement (LGE) cardiovascular magneti

175 d with cardiovascular magnetic resonance for late gadolinium enhancement (LGE) detection and quantifi

176 Stress CMR with late gadolinium enhancement (LGE) has also shown that MB

177 ent elevation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demonstrated

178 anced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in v

179 role of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been clarified

180 udies have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogeneity on magne

181 n time inversion-recovery (STIR) images, and late gadolinium enhancement (LGE) images were acquired.

182 Although late gadolinium enhancement (LGE) imaging by cardiac mag

183 D) from flow-limiting coronary stenosis, CMR late gadolinium enhancement (LGE) imaging is currently t

184 Late gadolinium enhancement (LGE) imaging overestimates

185 of CAD by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging.

186 dergoing cardiac magnetic resonance imaging, late gadolinium enhancement (LGE) in 17 patients, and T2

187 dial extracellular volume fraction (ECV) and late gadolinium enhancement (LGE) in children and young

188 Areas of late gadolinium enhancement (LGE) in each image were ass

189 nostic significance of left ventricular (LV) late gadolinium enhancement (LGE) in patients with atria

190 23.1 +/- 10.9 years), 25 (28%) had positive late gadolinium enhancement (LGE) in the ventricular myo

191 Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standar

192 Late gadolinium enhancement (LGE) is an important progno

193 as part of a CMR protocol including MPI and late gadolinium enhancement (LGE) is not well establishe

194 anced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is unresolved.

195 as to assess acute ablation injuries seen on late gadolinium enhancement (LGE) magnetic resonance ima

196 Myocardial fibrosis was detected by late gadolinium enhancement (LGE) MRI, and myocardial pe

197 shows that magnetic resonance imaging (MRI) late gadolinium enhancement (LGE) of the coronary vessel

198 and isolated LV subepicardial/midmyocardial late gadolinium enhancement (LGE) on contrast-enhanced c

199 uspected myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 200

200 Currently, late gadolinium enhancement (LGE) scans provide the only

201 Background Cardiac MRI late gadolinium enhancement (LGE) scar volume is an impo

202 beyond that achieved by the well-established late gadolinium enhancement (LGE) technique (which detec

203 Left ventricular hypertrophy (LVH) and late gadolinium enhancement (LGE) were independent predi

204 orted on the association of left atrial (LA) late gadolinium enhancement (LGE) with atrial voltage in

205 The presence of late gadolinium enhancement (LGE) yields a hazard ratio

206 yocardial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their ri

207 g short-axis slice of native T1 map, T2 map, late gadolinium enhancement (LGE), and automated extrace

208 0% male) underwent DT-CMR in diastole, cine, late gadolinium enhancement (LGE), and extracellular vol

209 segmental wall thickening percent, segmental late Gadolinium enhancement (LGE), and extracellular vol

210 s) at rest, hyperemia perfusion defect (PD), late gadolinium enhancement (LGE), and inducible WMA wer

211 ion to detecting myocardial fibrosis through late gadolinium enhancement (LGE), extracellular volume

212 pathy (HCM) myocardial fibrosis, detected by late gadolinium enhancement (LGE), is associated to a pr

213 arker of reactive interstitial fibrosis, and late gadolinium enhancement (LGE), representing replacem

214 tudy of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardiac magnetic reson

215 ibrosis of the myocardium is detectable with late gadolinium enhancement (LGE).

216 ography, and cardiac magnetic resonance with late gadolinium enhancement (LGE); all 3 tests were <24

217 as low native T1 (sphingolipid storage) and late gadolinium enhancement (LGE, scar).

218 d large transmural (volume of enhancement on late gadolinium enhancement [LGE] images >20%, n = 72) o

219 r-separated imaging, focal fibrosis imaging (late gadolinium enhancement [LGE]), and (1)H magnetic re

220 e, left ventricular function, and myocardial late gadolinium enhancement [LGE]), and metabolic parame

221 T2 relaxation times, ECV, myocardial edema, late gadolinium enhancement [LGE], and myocardial strain

222 3 years) underwent T2-weighted, tagging, and late gadolinium enhancement magnetic resonance imaging a

223 ents with LFLG-AS have higher ECV, iECV, and late gadolinium enhancement mass compared with high-grad

224 Late gadolinium enhancement mass was also similar in pat

225 mic microvascular resistance correlated with late-gadolinium enhancement mass (r=0.48; P=0.03) but no

226 entricular ejection fraction, and percentage late-gadolinium enhancement mass were 1.35+/-1.21 microg

227 l free-breathing, motion-corrected, averaged late-gadolinium-enhancement (moco-LGE) cardiovascular MR

228 I guidance, and gap lengths determined using late gadolinium enhancement MR images were correlated wi

229 luded T2-weighted, native T1/T2 mapping, and late gadolinium enhancement MR imaging.

230 We hypothesized that late gadolinium enhancement MRI (LGE-MRI) can identify l

231 lead tip placement through coregistration of late gadolinium enhancement MRI and cardiac computed tom

232 aracterize different areas of enhancement in late gadolinium enhancement MRI done immediately after a

233 o a 3-tesla MRI system where high-resolution late gadolinium enhancement MRI was used to identify the

234 patients receiving CRT underwent preimplant late gadolinium enhancement MRI, postimplant cardiac CT,

235 and gaps up to 1.4 mm were identified using late gadolinium enhancement MRI.

236 uals with clinical cardiovascular disease or late gadolinium enhancement (n = 167), and after replaci

237 ratio), early gadolinium enhancement ratio, late gadolinium enhancement, native T1 relaxation times,

238 Most of these patients were late gadolinium enhancement negative.

239 as measured in 27 subjects, all of whom were late gadolinium enhancement negative.

240 LV late gadolinium enhancement occurred with normal LV syst

241 At baseline, a lower extent of late gadolinium enhancement (odds ratio [OR]: 0.67 [95%

242 ction fraction was 51% (+/-17%), and 32% had late gadolinium enhancement on cardiac magnetic resonanc

243 e: 44 years) arrhythmic MVP patients with LV late gadolinium enhancement on cardiac magnetic resonanc

244 .2]) at baseline evaluation, the presence of late gadolinium enhancement on cardiac magnetic resonanc

245 Nineteen percent had late gadolinium enhancement on cardiac magnetic resonanc

246 lar ejection fraction (LVEF) >35% with >5.7% late gadolinium enhancement on cardiovascular magnetic r

247 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic r

248 e athletes but none of the controls revealed late gadolinium enhancement on cardiovascular magnetic r

249 ted catecholamine levels, RV dilatation, and late gadolinium enhancement on MRI, increased (18)fluoro

250 Diabetics without late gadolinium enhancement or inducible ischemia had a

251 was associated with increased occurrence of late gadolinium enhancement (P=0.004).

252 ich was mainly asymmetrical, and had similar late gadolinium enhancement patterns.

253 LVEF with both imaging modalities and higher late gadolinium enhancement per-patient prevalence as co

254 stic regression analysis after adjusting for late gadolinium enhancement, perfusion, and wall motion

255 All patients with ECG strain had midwall late gadolinium enhancement (positive and negative predi

256 e identified by wall motion abnormalities or late gadolinium-enhancement positivity.

257 In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvemen

258 The optimal cutoff for the extent of late gadolinium enhancement predictive of the composite

259 ages and fibro-fatty replacement in areas of late gadolinium enhancement presence.

260 iac magnetic resonance evidence of regional (late-gadolinium enhancement quantity, 6.4+/-8.0%) and di

261 02) and closely correlated with the areas of late gadolinium enhancement (R 0.98) with a small bias o

262 Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) and T

263 physiological abnormalities colocalized with late gadolinium enhancement scar, indicating a relations

264 dyskinetic area r=-0.49, P<0.0001; and RVOT late gadolinium enhancement score r=-0.33, P=0.01.

265 cumferential strain (Ecc), segmental area of late gadolinium-enhancement (SEE), microvascular obstruc

266 equences, and infarct size was determined by late gadolinium enhancement sequences and creatine kinas

267 Segmental comparison of (18)F-FDG-uptake and late gadolinium enhancement showed substantial overlap (

268 ven after excluding myocardial segments with late gadolinium enhancement, significant relationships b

269 Indexed late gadolinium enhancement significantly decreased in G

270 s and native T1 mapping, with no evidence of late gadolinium enhancement suggestive of replacement fi

271 ]; P=0.016) were higher in MVP patients with late gadolinium enhancement than in those without.

272 wall thickness was greater in segments with late gadolinium enhancement than without (20 +/- 6 mm vs

273 quent myocardial fibrosis as demonstrated by late gadolinium enhancement using cardiac magnetic reson

274 identifying focal ventricular fibrosis with late gadolinium enhancement (ventricular late gadolinium

275 xyglucose score was highest in segments with late gadolinium enhancement versus edema only and remote

276 issue was in good agreement with the 6-month late gadolinium enhancement volume (r=0.99) and correlat

277 In addition, late gadolinium enhancement was also assessed.

278 The presence of late gadolinium enhancement was also significantly assoc

279 Late gadolinium enhancement was assessed by using gradie

280 Late gadolinium enhancement was assessed with CMR.

281 gional LS and CS 2DST and 2DTagg to identify late gadolinium enhancement was compared using receiver

282 Myocardial fibrosis by late gadolinium enhancement was detected in 15.8% of the

283 Indeed, late gadolinium enhancement was independently associated

284 left ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid

285 Late gadolinium enhancement was present in >60% of overt

286 icular ejection fraction was 61 +/- 12%; and late gadolinium enhancement was present in 29% and ische

287 Myocardial late gadolinium enhancement was present in 4 (27%) of 15

288 LV late gadolinium enhancement was present in a primarily s

289 Plaque rupture was found in nearly 40% and late gadolinium enhancement was seen in nearly 40%, with

290 te infarcted versus noninfarcted segments by late gadolinium enhancement was similarly good for regio

291 After injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardia

292 eft ventricular dilation and the presence of late gadolinium enhancement were inversely correlated to

293 edian age: 40 years) MVP patients without LV late gadolinium enhancement were investigated by morphof

294 Both ECV and late gadolinium enhancement were more extensive in sarco

295 aplan-Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associate

296 t model, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for e

297 Regional left ventricular function and late-gadolinium enhancement were assessed by cardiac mag

298 t of patients with SCD (25%) had evidence of late gadolinium enhancement, whereas only 1 patient had

299 ify regional diffuse fibrosis not visible by late gadolinium enhancement, which was associated with i

300 isease represents sphingolipid accumulation; late gadolinium enhancement with high T2 and troponin el